Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Mr. Jeffrey  Frelick

Nome	Capitalizzazione di mercato
Edwards Lifesciences Corporation	0M
SofWave Medical Ltd.	0M
BIOLASE, Inc.	0M
Eiken Chemical Co., Ltd.	0M
QHSLab, Inc.	0M
Qlife Holding AB (publ)	0M
Vitrolife AB (publ)	0M
ReWalk Robotics Ltd.	0M
Sinocare Inc.	0M
Hyperfine, Inc.	0M

Bone Biologics Corporation

Bone Biologics Corporation Elenco dei concorrenti

Principali concorrenti